Skip to main content Scroll Top

Actualités

  • Accueil
  • Alzheimer
  • A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance
Posts les plus vus
Clear Filters
REGEnLIFE, la DeepTech de la NeuroTech française finaliste du Prix Galien USA 2025
REGEnLIFE, la DeepTech de la NeuroTech française finaliste du Prix Galien USA 2025
16 mars 2026
The Neuroprotective Effect Of A New Photobiomodulation Technique On Aβ25-35 Peptide-Induced Toxicity Dramatically Impact Gut Microbiota Dysbiosis
30 novembre 2019
Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer’s disease
1 octobre 2019
1 novembre 2022

A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance

Read the article
JAD Journal of Alzheimer's Disease

Blivet G, Relano-Gines A, Wachtel M, Touchon J.

J Alzheimers Dis. 2022;90(2):811-822. doi: 10.3233/JAD-220467.

PMID: 36189591 Clinical Trial.

Partagez cet article